GEA
ARQT icon

Glen Eagle Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

Glen Eagle Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400
Closed -$9.56K – 938
2021
Q3 		$9.56K Buy
400
+160
+67% +$3.65K ﹤0.01% 705
2021
Q2 		$6.55K Buy
+240
New +$6.76K ﹤0.01% 774

Other funds holding ARQT

FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Glen Eagle Advisors's ARQT Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Arcutis Biotherapeutics (ARQT) in Q4 2021, closing a stake of 400 shares — an estimated $9.56K sold.

Glen Eagle Advisors first reported a position in ARQT in Q2 2021 and held it in 2 quarters. The position peaked at $9.56K in Q3 2021. 93 funds tracked by Wall St. Rank hold ARQT as of Q4 2021.

  • Glen Eagle Advisors reported no remaining Arcutis Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 400 Arcutis Biotherapeutics shares in Q4 2021, an estimated $9.56K.
  • Glen Eagle Advisors first reported a position in Arcutis Biotherapeutics in Q2 2021 and held it in 2 quarters.
  • Glen Eagle Advisors's Arcutis Biotherapeutics position peaked at $9.56K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.